[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Carman Alenson Biography and Net Worth

Insider of Agios Pharmaceuticals

Currently, Carman Alenson is Vice President-Accounting, Treasury & Tax at Agios Pharmaceuticals, Inc.

She received an MBA and an undergraduate degree from Boston University.

What is Carman Alenson's net worth?: The estimated net worth of Carman Alenson is at least $95,567.06 as of June 21st, 2021. Ms. Alenson owns 1,777 shares of Agios Pharmaceuticals stock worth more than $95,567 as of November 15th. This net worth estimate does not reflect any other investments that Ms. Alenson may own. Learn More about Carman Alenson's net worth.
How do I contact Carman Alenson?: The corporate mailing address for Ms. Alenson and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Carman Alenson's contact information.
Has Carman Alenson been buying or selling shares of Agios Pharmaceuticals?: Carman Alenson has not been actively trading shares of Agios Pharmaceuticals in the last ninety days. Most recently, Carman Alenson sold 1,777 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $61.61, for a transaction totalling $109,480.97. Following the completion of the sale, the insider now directly owns 1,777 shares of the company's stock, valued at $109,480.97. Learn More on Carman Alenson's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 76,141 shares worth more than $2,110,887.90. The most recent insider tranaction occured on September, 26th when CFO Cecilia Jones sold 2,542 shares worth more than $124,634.26. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 9/26/2024.

Carman Alenson Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2021	Sell	1,777	$61.61	$109,480.97	1,777
4/15/2021	Sell	991	$54.00	$53,514.00
9/2/2020	Sell	250	$39.93	$9,982.50	184
12/26/2019	Sell	2,950	$50.09	$147,765.50
7/9/2018	Sell	272	$84.94	$23,103.68	272
1/12/2018	Sell	2,150	$75.00	$161,250.00	2,150

Carman Alenson Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $53.78

$52.74

$55.67

50 Day Range

MA: $46.44

$40.50

$60.46

2 Week Range

Now: $53.78

$20.96

$62.58

Volume

926,067 shs

Average Volume

704,416 shs

Market Capitalization

$3.07 billion

P/E Ratio

4.73

Dividend Yield

N/A

Beta

0.75